- Policy
- Price cut of Faslodex
- by Lee, Tak-Sun Oct 26, 2022 05:50am
- AstraZeneca's breast cancer treatment, Faslodex, will be a real match with Boryung's first generic Fulvet as it will be cut by 30% from the current upper limit starting next month due to a cut in drug prices following its entry into the generic. This is because the price has become almost similar to Boryung Fulvet, which has the same ingredie
- Opinion
- [Reporter's view] Two plays in the parliamentary audit
- by Kim, Jin-Gu Oct 25, 2022 05:46am
- A Member of Parliament asks about the need to introduce a prescription for active ingredients. Then, whether it was the Minister of Health and Welfare or the Minister of Food and Drug Safety, he replied that he sympathized with the purpose. There is a strong backlash from medical groups. This concludes the play. The same is true this year. Se
- Company
- Genuone challenges Trajenta’s non-listed patent...Why?
- by Kim, Jin-Gu Oct 25, 2022 05:46am
- Genuone Sciences has challenged the unlisted patents of Trajenta (linagliptin). Industry interpretations are that the move is the company’s strategy to remove uncertainties in releasing generic versions of Trajenta and to additionally attract CMO deals” According to industry sources on the 24th, Genuone Sciences filed a trial to co
- Company
- Cibinqo lands in general hospitals in Korea
- by Eo, Yun-Ho Oct 25, 2022 05:46am
- Pfizer’s second Janus kinases (JAK) inhibitor ‘Cibinqo (abrocitinib) has landed and may be prescribed at general hospitals in Korea. According to industry sources, Pfizer Korea’s new JAK1 inhibitor drug (abrocitinib) has passed the drug committee (DC) reviews of the ‘Big 5 tertiary hospitals’ of Korea including the Seoul National Uni
- Company
- GSK has signed a sales contract with GC Pharma & Kwang Dong
- by Eo, Yun-Ho Oct 25, 2022 05:46am
- GSK has signed a joint sales contract with two domestic companies, GC Pharma and Kwang Dong, to sell the shingles vaccine Shingrix. GSK Korea announced on the 24th that it signed a Co-Promotion and Distribution Partnership for Shingrix's domestic sales and marketing on the 21st. Through this partnership, GC Pharma and Kwang Dong will joint
- Policy
- Lenvima's PMS results for 6 years
- by Lee, Hye-Kyung Oct 25, 2022 05:45am
- The permission of Lenvima, a thyroid-targeted anticancer drug, will be changed based on the results of a six-year post-marketing survey conducted in Korea. The Ministry of Food and Drug Safety will prepare a change order (proposal) based on the results of the post-marketing investigation of Lenvima by Eisai Korea and conduct an opinion inqui
- Company
- Lyumjev can be prescribed in general hospitals
- by Eo, Yun-Ho Oct 24, 2022 06:08am
- The new fast-acting insulin ‘Lyumjev’ can now be prescribed at general hospitals in Korea. According to industry sources, Lilly Korea’s ‘Lyumjev (insulin lispro)’ has passed the drug committee (DC) reviews of various medical institutions including the Samsung Medical Center. Lyumjev, which was approved in Korea in December last y
- Company
- Will Onureg, an acute leukemia maintenance drug be listed?
- by Eo, Yun-Ho Oct 24, 2022 06:08am
- Attention is focusing on whether Onureg will be able to be listed on the insurance benefit list. According to related industries, Onureg of BMS Pharmaceutical Korea is expected to be submitted to the HIRA Cancer Disease Review Committee on the 2nd of next month. Onureg is the only oral maintenance of acute myeloid leukemia. It was approved in
- Policy
- How did Zerbaxa get recognized for its benefit?
- by Lee, Tak-Sun Oct 24, 2022 06:08am
- There is an item that Rep. Choi Jae-hyung of the People's Power, who has been criticized by the pharmaceutical industry for insisting on lowering generic drug prices during the parliamentary audit, is praising his salary registration. It is the super antibiotic Zerbaxa. At the HIRA parliamentary audit held on the 13th, he said, "200 to 300 pe
- Policy
- Will Gilead reclaim its throne in the HCV drug market?
- by Lee, Tak-Sun Oct 24, 2022 06:08am
- Fierce competition is being expected in the hepatitis C (HCV) treatment market with the launch of Gilead’s new treatment which is priced at a lower level than the current market leader. With the new product, Gilead is aspiring to reclaim the former glory that it had enjoyed dominating the market with Sovaldi. According to industry so
